论文部分内容阅读
目的通过检测喘息患儿FcεRI-β基因多态性与临床表现、药物疗效及哮喘相关性的研究,探讨该基因多态性对喘息患儿的易感性、疗效与预后的作用。方法选取住院喘息患儿146例,用荧光定量PCR法检测患儿FcεRI-β基因,其中AG、GG为风险基因型,共41例,AA为正常基因型,共105例;记录两组患儿的喘息发作程度、检测肺功能;记录两组临床疗效(雾化治疗、全身使用糖皮质激素、住院时间、后续治疗);出院后随访2年,记录两组患儿的哮喘发病率。结果风险型基因组与正常型基因组在喘息发作严重程度中的分布有统计学差异(P=0.003),风险型基因组较正常型基因组喘息发作严重;两组患儿在肺功能异常上无统计学差异(P=0.53);两组在雾化治疗上无统计学差异(P=0.74);两组在使用全身糖皮质激素上无统计学差异(P=0.21);两组在住院时间上无统计学差异(P=0.21);两组患儿在后续治疗上没有统计学差异,P=0.63>0.05;两组患儿在随访2年后,哮喘发病率上无统计学差异(P=0.13)。结论 FcεRI-β基因多态性与患儿的喘息发病相关,风险型基因是喘息发生的危险因素;风险型基因影响喘息发作的严重程度;但不是影响肺功能的主要因素;基因多态性不是影响疗效的主要因素;也不是发生哮喘的主导因素。
Objective To investigate the association between the polymorphism of FcεRI-β gene and clinical manifestations, drug efficacy and asthma in asthmatic children and explore the role of polymorphism in susceptibility, outcome and prognosis of asthmatic children. Methods A total of 146 children with asthma in hospital were enrolled in this study. Fetal immunofluorescence staining was used to detect the expression of FcεRI-β in children with AG and GG genotypes. A total of 41 cases were genotype AA with normal genotypes of 105 cases. The incidence of wheezing was measured and the pulmonary function was measured. The clinical efficacy of the two groups was recorded (atomization, systemic corticosteroids, hospital stay, follow-up treatment). The patients were followed up for 2 years after discharge and the incidence of asthma in both groups was recorded. Results There was a statistically significant difference in the severity of wheezing (P = 0.003) between the risk genotypes and the normal genotypes. The risk genotypes were more severe than those in the normal genotypes. There was no significant difference in the lung function between the two groups (P = 0.53). There was no significant difference between the two groups in the treatment of nebulization (P = 0.74). There was no significant difference between the two groups in the use of systemic glucocorticoid (P = 0.21) (P = 0.21). There was no significant difference in the follow-up treatment between the two groups (P = 0.63> 0.05). There was no significant difference in the incidence of asthma between the two groups (P = 0.13) . Conclusion The polymorphism of FcεRI-β is associated with the onset of wheeze in children. Risk gene is a risk factor for wheezing. Risk gene affects the severity of wheezing, but not the major factor affecting lung function. Gene polymorphism is not The main factor affecting the efficacy; nor is the dominant factor in the occurrence of asthma.